Table 2.
Vaccine type | Vaccine name | Manufacturer and country | WHO emergency use listing?*21 | Country | Approval date for paediatric use | Paediatric age indication (years) | |
1 | messenger RNA (mRNA) | BNT162b2 | Pfizer-BioNTech (USA/Germany) | Yes | Uganda Mauritius Morocco Seychelles South Africa Guinea Conakry Namibia Ghana Egypt Egypt Nigeria |
26 July 202136 August 202137 31 August 202137 9 September 202138 10 September 202139 10 November 202138 12 November 202140 16 November 202141 2 November 202142 28 November 202143 14 January 202244 |
12–17 12–17 12–17 12–17 12–17 12–17 12–17 15–17 15–18 12–15 16–17 |
2 | mRNA-1273 | Moderna (USA) | Yes | Guinea Conakry Nigeria |
10 November 202138 14 January 202244 |
12–17 16–17 |
|
3 | Viral vector | Ad26.COV2.S | Johnson & Johnson/Janssen (USA/Belgium) | Yes | Nigeria | 14 January 202244 | 16–17 |
4 | AZD1222 | Oxford-AstraZeneca (UK) | Yes | Nigeria | 14 January 202244 | 16–17 | |
5 | Covishield | Serum Institute of India | Yes | Nigeria | 14 January 202244 | 16–17 | |
6 | Sputnik Light | Gamaleya (Russia) | No | None | – | – | |
7 | Sputnik V | Gamaleya (Russia) | No | Nigeria | 14 January 202244 | 16–17 | |
8 | Inactivated virus | BBIBP-CorV | Sinopharm (China) | Yes | Morocco Nigeria |
31 August 202137 14 January 202244 |
12–17 16–17 |
9 | CoronaVac | Sinovac (China) | Yes | Zimbabwe | 1 November 202145 | 16–17 | |
10 | Covaxin | Bharat Biotech (India) | Yes | None | – | – | |
11 | Protein based | Corbevax | Biological-E (India) | No | None | – | – |
12 | Covovax | Serum Institute of India (India) | Yes | None | – | – | |
13 | NVX-CoV2373 | Novavax (USA) | Yes | None | – | – | |
14 | DNA | ZyCoV-D | Zydus Cadila (India) | No | None | – | – |
*As of 14 January 2022.
†Waiver granted for 16 and 17 year-olds to get any available COVID-19 vaccine if needed for educational (e.g school vaccine mandate, international institution admission/attendance requirements) and international travel purposes. Approvals in table indicated for vaccines currently available in Nigeria.4